Literature DB >> 28149759

ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer.

Viola W Zhu1, Sai-Hong Ignatius Ou2.   

Abstract

Entities:  

Year:  2016        PMID： 28149759      PMCID： PMC5233869          DOI： 10.21037/tlcr.2016.12.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  12 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

2.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Authors:  Daniel B Costa; Alice T Shaw; Sai-Hong I Ou; Benjamin J Solomon; Gregory J Riely; Myung-Ju Ahn; Caicun Zhou; S Martin Shreeve; Paulina Selaru; Anna Polli; Patrick Schnell; Keith D Wilner; Robin Wiltshire; D Ross Camidge; Lucio Crinò
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

3.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

4.  Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Authors:  Thomas H Marsilje; Wei Pei; Bei Chen; Wenshuo Lu; Tetsuo Uno; Yunho Jin; Tao Jiang; Sungjoon Kim; Nanxin Li; Markus Warmuth; Yelena Sarkisova; Frank Sun; Auzon Steffy; AnneMarie C Pferdekamper; Allen G Li; Sean B Joseph; Young Kim; Bo Liu; Tove Tuntland; Xiaoming Cui; Nathanael S Gray; Ruo Steensma; Yongqin Wan; Jiqing Jiang; Greg Chopiuk; Jie Li; W Perry Gordon; Wendy Richmond; Kevin Johnson; Jonathan Chang; Todd Groessl; You-Qun He; Andrew Phimister; Alex Aycinena; Christian C Lee; Badry Bursulaya; Donald S Karanewsky; H Martin Seidel; Jennifer L Harris; Pierre-Yves Michellys
Journal:  J Med Chem       Date:  2013-06-26       Impact factor: 7.446

5.  Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Shirish M Gadgeel; Alice T Shaw; Ramaswamy Govindan; Leena Gandhi; Mark A Socinski; D Ross Camidge; Luigi De Petris; Dong-Wan Kim; Alberto Chiappori; Denis L Moro-Sibilot; Michael Duruisseaux; Lucio Crino; Tommaso De Pas; Eric Dansin; Antje Tessmer; James Chih-Hsin Yang; Ji-Youn Han; Walter Bordogna; Sophie Golding; Ali Zeaiter; Sai-Hong Ignatius Ou
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

6.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

7.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Authors:  Sai-Hong Ignatius Ou; Jin Seok Ahn; Luigi De Petris; Ramaswamy Govindan; James Chih-Hsin Yang; Brett Hughes; Hervé Lena; Denis Moro-Sibilot; Alessandra Bearz; Santiago Viteri Ramirez; Tarek Mekhail; Alexander Spira; Walter Bordogna; Bogdana Balas; Peter N Morcos; Annabelle Monnet; Ali Zeaiter; Dong-Wan Kim
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

8.  Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

Authors:  S-H I Ou; P A Jänne; C H Bartlett; Y Tang; D-W Kim; G A Otterson; L Crinò; P Selaru; D P Cohen; J W Clark; G J Riely
Journal:  Ann Oncol       Date:  2014-02       Impact factor: 32.976

9.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

10.  Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Authors:  Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Jürgen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Santosh Sutradhar; Siyu Li; Tomasz Szczudlo; Alejandro Yovine; Alice T Shaw
Journal:  Lancet Oncol       Date:  2016-03-11       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.